Authors' objectives:

The aim of this study was to summarize the available information on the use of Lubiprostone (Amitiza), manufactured by Sucampo Pharmaceuticals, Inc. (marketed by Takeda Pharmaceuticals).

Authors' recommendations: Lubiprostone offers clinicians another option for the treatment of chronic idiopathic constipation. Current evidence suggests that its unique mechanism of action, tolerability, and safety profile make it a useful additional option FDA approval for lubiprostone use in patients >65 years of age may be a potential advantage when compared with tegaserod. The budget impact of lubiprostone should be similar to that of tegaserod because it is an alternative treatment option rather than a replacement. Comparative studies are needed to determine which treatment option is the most efficacious, safe, and cost effective. While lubiprostone has been shown to be effective in the management of chronic constipation, it should not be indicated as first-line therapy because current standard treatment options are less costly with fewer side effects. Until more evidence is available, lubiprostone should be reserved for patients with severe constipation who are refractory to other treatments.

Authors' methods: Overview

Project Status: Completed

URL for project: http://www.cadth.ca/media/pdf/E0020_lubiprostone_edrug_e.pdf

Year Published: 2007

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Canadian Agency for Drugs and Technologies in Health

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright: Canadian Agency for Drug and Technologies in Health (CADTH)